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A phase I study was carried out to determine the optimal dose and administration schedule for combined UFT plus
gemcitabine therapy in patients with non-small cell lung cancer. Twenty-four patients (including 11 patients previously treated
with cisplatin as the key drug) received oral UFT 400 mg m
72 on days 1 to 14 with intravenous infusions of gemcitabine
(800 mg m
72 on days 8 and 15, or 900 mg m
72 on days 8 and 15, or 900 mg m
72 on days 1, 8 and 15). The most
appropriate dosing option appeared to be 400 mg m
72 per day of oral UFT for 14 consecutive days with 900 mg m
72
gemcitabine on days 8 and 15. Eight of the 24 patients achieved partial response. The combination chemotherapy UFT and
gemcitabine was well tolerated and may beneﬁt patients with advanced non-small cell lung cancer. A multicentre phase II
study using a 3-weekly regimen is in progress.
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Although treatment of unresectable non-small cell lung cancer has
begun to yield better results following the adoption of combination
chemotherapy using cisplatin (CDDP) as the key drug, the median
survival period of these patients still remains dismal at 6–10
months (Non-small cell lung cancer collaborative Group, 1995).
Therefore, more efﬁcacious treatment employing modalities that
would entail minimal adverse effects, high efﬁcacy rates and
prolonged survival is needed.
Gemcitabine (GEM), a new anticancer drug structurally resem-
bling cytosine arabinoside (Ara-C), has been shown to have high
anti-tumour activity and minimal adverse effects (Hertel et al,
1988). Thus, it is reasonable to assume that gemcitabine could
be better tolerated in older patients or patients with poor perfor-
mance status (PS).
UFT, an oral antimetabolite compound composed of tegafur and
uracil (1:4), also has mild adverse effects (Yamada et al, 1980).
Earlier preclinical studies have demonstrated that it can inhibit
tumour growth and prolong patients’ lives through inhibition of
tumour neovascularisation (Maehara et al, 1988; Ota et al, 1988).
Although the response rate of non-small cell lung cancer
patients to UFT as a single agent is reported to be 6–8%(Keicho
et al, 1986; Shimizu et al, 1986),combination chemotherapy using
UFT plus cisplatin in those patients demonstrated a response rate
of 35% and an extremely low incidence of adverse events(Ichinose
et al, 1995).
Thus, both GEM and UFT are antimetabolites with minimal
adverse effects that could be expected to provide a better quality
of life (QOL). These two drugs inhibit DNA synthesis via different
pathways, i.e., DNA chain termination and thymidylate synthase
(TS) inhibition, respectively. We can therefore expect synergistic
effects when they are used in combination. Based on this premise,
a phase I study was carried out to determine the optimal dose and
administration schedule for combined UFT+GEM therapy in
patients with advanced non-small cell lung cancer.
PATIENTS AND METHODS
The subjects were patients aged 80 years or younger with stage IIIB
or IV non-small cell lung cancer (cytologically and histologically
conﬁrmed). They were not amenable to radical irradiation, with
a PS score (ECOG) of 0–2 and a predicted survival of at least 3
months. The subjects were recruited at least 28 days after the
previous treatment. The eligibility criteria in terms of organ func-
tions were as follows: bone marrow function: total leukocyte count
4000 ml
71 or higher, neutrophil count 2000 ml
71 or higher and
platelet count 100000 ml
71 or higher; liver functions: serum AST
and ALT levels not more than twice the upper limit at the institu-
tion, serum total bilirubin level under the upper limit at the
institution; renal functions: serum creatinine levels under the upper
limit at the institution; pulmonary function: SpO2 90% or greater.
The exclusion criteria were as follows: presence of pericardial
effusion or pleural effusion necessitating drainage, interstitial pneu-
monia diagnosable on plain chest X-ray, history of serious cardiac
dysfunction or episodes of ischaemia within the preceding 3
months, or symptomatic brain metastasis. Written consent was
obtained from each patient.
Drug administration
UFT was administered orally twice a day (before the morning and
evening meals), at a ﬁxed daily dose of 400 mg m
72, up to a maxi-
mum of 600 mg day
71. Capsules containing 100 mg UFT were
used. When an odd number of capsules was used for a daily dose
of, e.g., 500 mg, the dose was divided to 300 mg for the morning
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physiological saline, and then diluted further with physiological
saline or 5% glucose to a volume of 250 ml. The GEM solution
was administered by intravenous drip infusion over 30 min. On
the day of GEM administration, a complete blood count was
checked and the drug was administered only when the leukocyte
count was 2000 ml
71 or higher and the platelet count was
70000 ml
71 or higher. If these requirements were not met, the
drug administration was postponed for a maximum of 4 days.
The course of therapy was repeated at 28-day intervals. Recovery
from bone marrow toxicity was conﬁrmed before initiation of a
further course.
Dose escalation procedure and drug delivery schedule
(Table 1)
In this phase I study, the UFT dose administration schedule was
ﬁxed at 400 mg m
72 per day on days 1–14. GEM was adminis-
tered in incremental doses; 800 mg m
72 on days 8 and 15 in
level one, 900 mg m
72 (the recommended dose for combined
GEM therapy in Japan) on days 8 and 15 in level two, and
900 mg m
72 on days 1, 8 and 15 in level 3.
Evaluation
Drug toxicity was evaluated after two courses of therapy. Dose-
limiting toxicity (DLT) was deﬁned as the presence of grade 4
leukopenia, neutropenia or thrombocytopenia according to WHO
criteria for adverse reactions, fever of 388 or higher attributable
to neutropenia, inability to ﬁt the administration criteria for more
than 5 days after the intended day of GEM administration, grade-3
or higher non-haematological toxicity, or unexpected serious
adverse reactions. At least three patients were enrolled in level
one, and three more patients were included when DLT occurred
in not more than one patient. Then, the study was carried over
to the next level when DLT occurred in not more than two
patients. When DLT occurred in three or more patients, another
six patients were included, and the dose causing DLT in 50% of
the patients was determined and regarded as the maximum toler-
ated dose (MTD), the preceding dose being considered as the
recommended dose.
RESULTS
Twenty-four patients were enrolled between December 1999 and
June 2000. Table 2 shows the patient characteristics. The 24
patients were comprised of 16 men and eight women, with a
median age of 72 years (range, 49–80 years). Eleven patients had
previously received chemotherapy with CDDP as the key drug.
The number of patients included in each level is shown in Tables
3 and 4. Each patient received 1–4 courses of therapy, with a
median of three courses.
Toxicity (Tables 3 and 4)
General oedema and capillary vasculitis in the lower legs occurred
in one patient at level three, and this patient therefore received
only one course of therapy. DLT occurred in one case (neutrope-
nia) at level one. Three more patients were added, with DLT being
noted in only one of the six total patients; the dose was then
advanced to level two. At level two, thrombocytopenia was
observed in one patient, and following the addition of another
three patients, the frequency of thrombocytopenia observed was
1 out of 6. Although GEM administration on day 15 was post-
poned in two patients, the drug was administered within the
subsequent 4 days. Twelve patients were studied in level three.
Grade-3 hepatotoxicity and nausea was found in one patient.
Leukopenia, neutropenia and thrombocytopenia occurred in one,
two and three patients, respectively, and fever associated with
leukopenia was noted in one patient. No central nerve system toxi-
city nor any lethargy was observed in this treatment. Since GEM
administration scheduled on day 15 was not possible within the
subsequent 4 days in six patients, the dose at this level was
regarded as the MTD, and the level two dose was considered as
the recommended dose.
Response
Signiﬁcant response was observed in eight out of the total of 24
patients. The overall response rate was 33% (95% conﬁdence inter-
val: 14 to 52%). The response rate among the chemo-naı ¨ve patients
was 45% (5 out of 11), and that for the second-line use was 23%
(3 out of 13).
DISCUSSION
CDDP-based chemotherapy has been demonstrated to result in
prolonged survival and improved QOL in patients with advanced
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Table 1 Dose escalation procedure and drug delivery schedule
Schedule
Level Drug Dose Day 1 Day 8 Day 15
1 UFT 400 mg m
72 =====================
GEM 800 mg m
72 GG
2 UFT 400 mg m
72 =====================
GEM 900 mg m
72 GG
3 UFT 400 mg m
72 =====================
GEM 900 mg m
72 GG G
GEM=gemcitabine; ====oral UFT treatment 14 days; G=gemcitabine intravenous
drip infusion.
Table 4 Haematological toxicities
WBC Neu PLT Schedule
Level n Grade 3/4 3/4 3/4 delay/skip
1 6 2/0 1/1 0/0 0/0
2 6 2/0 3/0 2/1 2/0
3 12 7/1 6/2 5/3 0/6
WBC=leukopenia; Neu=neutropenia; PLT=thrombocytopenia.
Table 3 Non-haematological toxicities
Liver Renal Nausea Fever Other
Level n Grade 2/3 2/3 2/3 1/2
1 6 1/0 0/0 3/1 0/0
2 6 0/0 0/0 0/0 1/0
3 12 0/1 1/0 0/1 1/1 general oedema
Table 2 Patient characteristics
Total Patients Number 24
Age Median (Range) 72 (49–80)
Gender (Men/Women) 16/8
Performance Status (ECOG)
PS 0–1/2 18/6
Stage (IIIB/IV) 4/20
Histology
Adenocarcinoma/Squamous cell Carcinoma 20/4
Previous Chemotherapy
Naı ¨ve/Treated with cisplatin 13/11
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tive Group, 1995). Several newer agents available for clinical use
in the 1990’s have been shown to provide even greater survival
beneﬁts than conventional drugs when used in combination with
cisplatin (Bunn and Kelly, 1998). Among such new drugs, GEM
is a new pyrimidine nucleoside analogue having antitumour activ-
ity with a unique mechanism of action (Hertel et al, 1988).
Monotherapy with GEM has been shown to yield an efﬁcacy rate
of 20% or higher when used in patients with advanced non-small
cell lung cancer (Gatzemeier et al, 1996; Abratt et al, 1994; Fukuo-
ka et al, 1996). Its administration has also been shown to be
associated with a low incidence of adverse reactions such as bone
marrow suppression, nausea, vomiting and hair loss, suggesting
that it might be well tolerated by elderly patients (Shepherd et
al, 1997; Martin et al, 1997). Earlier studies have demonstrated that
GEM could be combined with most other agents because of its
unique mechanism of action as well as non-overlapping safety
proﬁle with these agents (Cortes-Funes et al, 1997). In particular,
the efﬁcacy rate of GEM administered in combination with CDDP
has been reported to be 40–60% (Sandler and Ettinger, 1999).
However, combination chemotherapy with CDDP could prove to
be difﬁcult in elderly patients and in those with a poor PS.
The oral antimetabolite UFT (a drug composed of tegafur and
uracil mixed at the ratio of 1:4) has been shown in earlier studies
to inhibit tumour growth and prolong survival through inhibition
of tumour neovascularization. This drug also has minimal adverse
effects and is presumed to be well tolerated in elderly patients. UFT
has also been used in postoperative adjuvant chemotherapy against
earlier stages of non-small cell lung cancer (Wada et al, 1996). The
efﬁcacy and survival rate of combination chemotherapy with UFT
and CDDP are also reported to be favourable (Ichinose et al, 1995,
2000).
Chemotherapeutic regimens having low toxicity and utility in
patients of advanced age or with poor PS are of major relevance
in the treatment of non-small cell lung cancer in the future. In this
regard, both GEM and UFT are antimetabolites with minimal
adverse effects and offer promise for improvement in the QOL
of these patients. They are expected to exert synergistic effects as
they inhibit DNA synthesis via different pathways, i.e., DNA chain
termination and TS inhibition, respectively. Synergism for GEM
and 5-Fluorouracil (5-FU) combinations was found in colon cancer
cell lines (Hagag et al, 1999)
The same concept combination chemotherapies with 5-FU
and GEM have been reported as follows; a phase I study of
folic acid plus 5-FU and GEM for solid tumour malignancies
(Madajewicz et al, 2000), and a phase II study for advanced
pancreatic cancer of 5-FU+GEM (Cascinu et al, 1999). Accord-
ing to these reports, the response rates for colon cancer and
pancreas cancer were 28.5% and 3.7%, respectively. However,
clinical beneﬁts were obtained in 51% of patients with pancreas
cancer, and this combination therapy is considered active treat-
ment. Although other phase I studies of GEM in combination
with UFT for treatment of gastrointestinal solid cancers have
been conducted (Philip et al, 1999), the optimal dosing sche-
dule has not yet been determined. A phase II study of
UFT+GEM and leucovorin for advanced pancreatic carcinoma
demonstrated a high response rate (16%) for this treatment
(Feliu et al, 2000).
In the present study in patients with non-small cell lung cancer,
GEM was administered in incremental doses of 800 mg m
72 on
days 8 and 15 in level one and 900 mg m
72 (the recommended
dose for combination therapy in Japan) on days 8 and 15 in level
two. UFT was administered orally for 14 consecutive days at the
ﬁxed dose of 400 mg m
72 per day. GEM was administered in
two schedules; on days 8 and 15 in levels one and two, and on days
1, 8 and 15 in level three. The administration on days 1, 8 and 15
in level three was associated with more severe haematologic toxi-
city, with the nadir usually occurring on day 15. Thus, GEM
administration was not possible on day 15 in 50% of the patients
at this level.
One important objective for the treatment of patients of
advanced age or with poor PS in outpatient clinics is to administer
a chemotherapeutic regimen on a weekly basis. Thus, severe bone
marrow suppression and the inability to comply with the dosing
schedule will be major deterrent factors. An in vitro study showed
that anti-tumour cell activity of GEM was higher with previous 5-
FU administration, compared to when 5-FU was given afterwards
(Rauchwerger et al, 2000). Since oral UFT metabolises to make
5-FU, signiﬁcantly higher levels of 5-FU were found on day 5 than
day 1 in pharmacokinetic studies (Ho et al, 1998). In addition, the
metabolic mechanism of UFT on day 1 would prevent synergism
between GEM and UFT. Taking these into consideration, the level
two regimen (oral UFT 400 mg m
72 per day for 14 consecutive
days+GEM 900 mg m
72 on days 8 and 15) appears to be the most
appropriate dosing option. Since the nadir of blood toxicity at level
two was commonly found on days 16–18, a 3 weekly cycle might
also be possible.
The overall response rate was observed in 33% of the patients in
the current study. Among chemo-naive patients, the response rate
was up to 45%, suggesting that the treatment could also be effec-
tive as primary treatment, even taking into consideration the
incidence of toxicities. In addition, among the patients who had
received previous chemotherapy with cisplatin, the response rate
was 23%, suggesting the potential utility of the regimen as
second-line chemotherapy. Based on the results of this phase I
study, a multicentre cooperative group phase II study in chemo-
naive patients with non-small cell lung cancer is now under way.
This phase II study will be using a 3-weekly regimen consisting
of UFT 400 mg m
72 per day for 14 days and GEM 900 mg m
72
on days 8 and 15. The dose may be elevated to 1000 mg m
72 in
a second course if the incidences of bone marrow suppression
are acceptable.
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